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Abstract 
Objective.  Women with menstrually related mood disorders (MRMD) have substantial rates of 
physical and sexual abuse, are more sensitive to experimental pain stimuli than women 
withoutnon-MRMD women, and endorse increased sensitivity to interpersonal rejection 
(emotional pain) in the premenstrual phase.  For the first time, this study examined physical and 
emotional pain sensitivity in women with MRMD and in non-MRMD controls as a function of 
abuse history. Methods.  A total of 126 women (63 MRMD, 34 with an abuse history and 63 
non-MRMD, 31 with an abuse history)  were evaluated for: (1) sensitivity to cold pressor and 
forearm ischemic pain; (2) emotional pain sensitivity based on daily prospective ratings of 
sensitivity to interpersonal rejection; and (3) basal plasma cortisol and norepinephrine (NE) 
concentrations.  Exploratory analyses examined relationships between plasma cortisol and NE 
concentrations and physical pain sensitivity.   
Results.  Abused MRMD Wwomen with MRMD and an abuse history showed increased 
sensitivity to both cold pressor and ischemic pain and lower basal cortisol concentrations, an 
effect not seen in the non-MRMD women.  However, abused non-MRMD women with an abuse 
history showed increased sensitivity to emotional pain relative to non-MRMD women with no 
such history.  In all subjects, the expected relationship between greater plasma cortisol 
concentration and reduced sensitivity to physical pain was observed.  While only in women with 
MRMD women only, plasma NE predicted pain sensitivity. 
Conclusions.  MRMD status moderates the effect of a history of abuse on both physical and 
emotional pain sensitivity.  The results also suggest that the hypocortisolemia documented in the 
MRMD women with MRMD and an abuse history may contribute to their greater sensitivity to 
noxious experimental stimuli.  This study adds to a growing body of evidence suggesting that a 
history of abuse may identify a clinically distinct subgroup of MRMD women with MRMD. 
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 Abuse rates for women in the United States are staggering, with more than one third of 
women from the general population having experienced sexual or physical abuse (Resnick, 
Kilpatrick, Dansky, Saunders, & Best, 1993).  The public health significance of such experiences 
in women is underscored by the well-established links between histories of abuse and psychiatric 
(Kendler et al., 2000) as well as medical illness (Felitti, 1998; Leserman et al., 1996), especially 
pain-related disorders (e.g., Sachs-Ericsson, Cromer, Hernandez, & Kendall-Tackett, 2009; 
Finestone et al., 2000; Irish, Kobayashi, & Delahanty, 2010).  However, the mechanisms 
underlying the association of abuse with clinical pain syndromes are unclear.   
Since experimental pain sensitivity is predictive of clinical pain (R. R. Edwards, Doleys, 
Fillingim, & Lowery, 2001; Fillingim, Maixner, Kincaid, Sigurdsson, & Harris, 1996), a handful 
of studies have investigated the association of abuse histories with experimental pain responses 
in clinical pain patients (Fillingim et al., 1997; Scarinci, McDonald-Haile, Bradley, & Richter, 
1994; Whitehead, Crowell, Davidoff, Palsson, & Schuster, 1997).  However, these studies have 
yielded mixed results that could result from differences in the nature of the noxious stimuli used 
or in the clinical population studied.  Moreover, there is substantial evidence that chronic pain 
induces remodeling of central nervous system pathways involved in processing painful stimuli 
(Eide, 2000; Staud, Vierck, Cannon, Mauderli, & Price, 2001; Fillingim, Maixner, Kincaid, & 
Silva, 1998).  Thus, studies in patients with established clinical pain may obscure the ability to 
examine biobehavioral and historical factors contributing to the development of clinical pain.   
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Studies examining abuse history and sensitivity to noxious stimuli in pain free samples are 
comparatively rare.  Fillingim & Edwards (2005) found in a university sample that a history of 
childhood sexual or physical abuse was associated with decreased sensitivity to suprathreshold 
thermal heat stimulation in women, but not in men.  Similarly, Granot et al., (2011) found that a 
history of sexual abuse in women was associated with elevated heat pain thresholds (decreased 
pain sensitivity), but also elevated pain intensity ratings.  
Studies examining stress-responsive endogenous pain regulatory mechanisms, including plasma 
cortisol and norepinephrine (NE) may be particularly relevant to understanding alterations in 
pain sensitivity in populations with an abuse history for two reasons: 1) alterations in cortisol and 
NE have been consistently documented in women with abuse histories, though the results are 
mixed regarding the directional differences of the effects in women with a history of abuse  (e.g. 
Girdler, et al. 2003, 2007; Heim, et al. 2000 (in JAMA), 2001, 2010; Young et al., Biol 
Psychiatry 2004), potentially due to differences across studies in lifetime psychiatric illness or 
psychotropic medication use (e.g. Girdler, et al. 2003, 2007; Heim, et al. 2001, 2010); and 2) 
cortisol and NE are among several stress-responsive endogenous pain regulatory mechanisms.  
The relationship of higher cortisol and NE concentrations to decreased  pain sensitivity has been 
observed in humans (al’Absi, Petersen, & Wittmers, 2000, 2002; Girdler et al., 2005; Straneva et 
al., 2002; Mechlin et al., 2005 ), and is thought to reflect an integrated physiological response as 
part of the defense reaction.  No studies of which we are aware have examined the relationship of 
stress-responsive endogenous pain regulatory mechanisms and pain sensitivity in women with 
abuse histories.   
 Of additional relevance to understanding pathophysiological mechanisms that link abuse 
to alterations in pain processing may be studies in women with a menstrually related mood 
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disorder (MRMD).  Menstrually related mood disorders are characterized by emotional and 
physical symptoms that appear during the premenstrual (luteal) phase of the menstrual cycle and 
remit with the onset of menses (Cunningham, Yonkers, O’Brien, & Eriksson, 2009). During the 
luteal phase, women with a MRMD show equivalent impairment in quality of life as patients 
with major depression, PTSD or panic disorder (Freeman et al., 2003).  While emotional 
symptoms are the diagnostic hallmark of MRMDs, somatic symptoms are prevalent and 
contribute to functional impairment (Steiner et al., 2001). Women with a MRMD are much more 
likely to have a history of both physical and sexual abuse (Girdler et al., 2003, 2007; Golding, 
Taylor, Menard, & King, 2000), and women with a MRMD arehave been shown to be more 
sensitive to experimental pain stimuli than controls (Fillingim et al., 1997; Straneva et al., 2002). 
However, no studies to date have examined the association of abuse histories with pain 
sensitivity in MRMD women with a MRMD.  
  The aims of the current study were two-fold: 1) to examine the independent as well as 
interactive effects of a MRMD diagnosis and a history abuse on physical pain sensitivity, 
emotional pain sensitivity, and endogenous pain regulatory mechanisms; and 2) to examine the 
relationship of endogenous pain regulatory mechanisms and pain sensitivity. We hypothesized 
that an abuse history would predict a unique pain and neuroendocrine phenotype in women with 
a MRMD compared women without a MRMD (i.e., that MRMD x Abuse history interactions 
would emerge) for the following reasons: 1)Based on our prior research showing that women 
with a MRMD women are more sensitive to laboratory-based physical pain stimuli 
(hyperalgesia) than non-MRMD women without a MRMD (Straneva et al., 2002 Fillingim et al., 
1995), while; 2)the literature summarized above indicating that in non-MRMD women without a 
MRMD, an abuse history is associated with hypoalgesia to painful stimuli; 3) the evidence that 
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women with women with a MRMD exhibit blunted HPA-axis function women without a MRMD 
(Girdler, Straneva, Light, Pedersen, & Morrow, 2001; Redei & Freeman, 1993; Straneva et al., 
2002); and 4) our prior work showing that only in women with a MRMD does women only, a 
history of abuse predicts lower plasma NE – an effect not seen in non-MRMD women with a 
history of prior abuse (Girdler et al., 2003).,  Based on the paucity of studies to date that have 
examined the relationship between neuroendocrine markers and pain sensitivity in women with 
prior abuse, no a priori hypotheses were generated regarding these relationships.  Thus, analyses 
involving neuroendocrine markers and pain sensitivity are exploratory.  
 
Methods 
Participants 
 Women were recruited from Chapel Hill, North Carolina, U.S.A. and the surrounding 
area primarily via advertisements placed in local periodicals.  These advertisements either 
targeted women with severe premenstrual symptoms (for the MRMD group) or women with no 
premenstrual symptoms (non-MRMD group).  Approximately 15% of the women with a MRMD 
sample were recruited via the University of North Carolina Center for Women’s Mood Disorders 
website. In order to obtain equal proportions of women with prior abused women in both the 
MRMD and non-MRMD groups, it was necessary to also selectively advertise for non-MRMD 
with a history of abuse survivors. Initial power analyses indicated that 60 women per MRMD 
group would yield 92% power to detect a difference of 250 seconds (sd = 342 seconds) in 
ischemic pain tolerance.  AA total of 126 women (63 MRMD, 34 with abuse and 63 non-
MRMD, 31 with abuse) were studied,. All women were in good health, without current chronic 
medical conditions, including pain-related disorders or DSM-IV Axis I psychiatric disorders, 
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including post-traumatic stress disorder (PTSD). None of the subjects were taking prescription 
medication or used over-the-counter analgesics excessively (> 10/month).  
Procedures 
 Participants were screened for medical history and instructed on the daily record of 
severity of problems (DRSP) form (Endicott, Nee, & Harrison, 2006) that was used to confirm 
MRMD or non-MRMD status (see below). ).  For education, women were assigned a score (1-4) 
based on degree: (1) less than a high school education, (2) high school degree, (3) college 
degree, or (4) post-graduate degree. After confirming MRMD status, participants were assessed 
for Axis I psychiatric disorders using the MINI international neuropsychiatric interview 
(Sheehan et al., 1998), and abuse history using a validated interview (Leserman et al.,1997).  
Confirming MRMD diagnosis  
 During an initial enrollment session, participants were screened for medical history and 
instructed on the daily record of severity of problems (DRSP) form (Endicott, Nee, & Harrison, 
2006) that was used to confirm MRMD or non-MRMD status.  All women completed the Daily 
Record of Severity of Problems (DRSP) on a daily basis for two to three menstrual cycles. This 
measure allows quantification of the severity of physical, emotional and behavioral symptoms, 
using a 6 point scale (1=absent, 2=minimal; 3=mild; 4=moderate; 5=severe; 6=extreme). 
Participants were classified as having MRMD if they met all of the following: (1) at least a 30% 
change in emotional symptom severity between the seven luteal phase days preceding menses 
compared with follicular phase days 4–10; (2) a rating of emotional symptoms as moderate, 
severe or extreme on at least two of the seven premenstrual days; (3) remission of symptoms 
within three days of the onset of menses followed by a clear symptom free period (≥ six 
consecutive days) during the early-to-mid follicular phase and (4) criteria 1-3 met in at least two 
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menstrual cycles (Endicott et al., 2006; Rubinow, Roy-Byrne, Hoban, Gold, & Post, 1984). Non-
MRMD women had: (1) only minimal emotional symptoms occurring on two or fewer days 
during the premenstrual week; and (2) less than a 30% change in symptom severity from the 
luteal to the follicular phase confirmed in two menstrual cycles. 
  
Quantifying emotional pain sensitivity 
 Sensitivity to interpersonal rejection (or emotional pain sensitivity) was measured with 
the following item from the DRSP: “Was more sensitive to rejection or my feelings were easily 
hurt”. This item is similar to emotional rejection items used in other research evaluating the 
connection between emotional and physical pain (DeWall et al., 2010).  Emotional pain 
sensitivity ratings from the first menstrual cycle only were analyzed in order to avoid the 
possible therapeutic effect of continuous daily ratings on emotional symptoms (Blake, 
Salkovskis, Gath, Day, & Garrod, 1998).  Follicular phase emotional pain sensitivity was based 
on the average ratings for days 1-14 of menstrual cycle and luteal phase emotional pain 
sensitivity was based on average ratings for days 15 through the end of the first menstrual cycle.  
Psychiatric history assessment  
After meeting MRMD or non-MRMD status, women came for a second session during 
which all women were evaluated for past depressive disorders (e.g. major depressive disorder, 
chronic depression), anxiety disorders (e.g. panic disorder, generalized anxiety disorder) and 
post-traumatic stress disorder (PTSD) using the MINI Psychiatric interview (Sheehan et al., 
1998). Women with current psychiatric disorders were excluded from participation, Full 
remission from depressive disorders for 1 year and from other Axis I disorders for 3 years was 
required.  For analytical purposes, all histories of depressive disorders were considered together 
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as ‘any depressive disorder’ and all histories of anxiety disorders were considered together as 
‘any anxiety disorder’, except for histories of PTSD which was considered separately.  
 
 
 Following the MINI, women were assessed for abuse histories.  Sexual abuse included 
the following experiences where force or threat of harm is used: 1) touching the subject's breasts, 
pubic area, vagina or anus with hands, mouth or objects;, 2) making the subject touch the 
perpetrator's pubic area or anus with hands, mouth, or objects;, or and 3) vaginal or anal 
intercourse.  Force or threat was not required for coding sexual abuse in children (< 13 years of 
age), if it was implied by the age differential between victim and perpetrator.  Physical abuse is 
defined as incidents separate from sexual abuse that included: 1) life threat (physically attacked 
with the intent to kill or seriously injure), and 2) other physical abuse (beaten up, hit, burned).  
This instrument also allows for a quantitative measure of abuse severity (range 0 – 6), calculated 
as follows: if sexual abuse involving only touch (+1) versus rape (+2); if 1 - 3 physical abuse 
experiences (+1) versus more than 3 physical abuse experiences (+2); if serious injury during 
sexual abuse (+2).  Because of the relatively small cell sizes associated with physical versus 
sexual abuse, women with any sexual or physical abuse history were combined into one group 
(Any Abuse) for analyses.  
Psychiatric history assessment  
 All participants were scheduledtested during the luteal phase of the menstrual cycle, 5-12 
days after home urine ovulation testing (ClearPlan Easy®) indicated the luteinizing hormone 
surge that indicatesprecedes ovulation.  Cycle phase was subsequently confirmed based on serum 
progesterone concentrations. To ensure that subjects were hydrated, each was required to 
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consume eight, eight-ounce glasses of water on the day prior to testing and one eight-ounce glass 
and a low fat breakfast the morning of testing (confirmed with diaries). Subjects were asked to 
refrain from over-the-counter medications 24 hours prior to testing, from caffeine, exercise and 
alcohol the day of testing, and from nicotine one hour prior to testing (confirmed via interview).  
Subjects who had been ill within 7 days of testing or who had fewer than 6 hours of sleep the 
previous night were rescheduled.  All laboratory testing began between 7:00 a.m. and 9:30 a.m.  
Groups did not differ in laboratory start time (median time for each group was 9:00 a.m.).  An 
intravenous (I.V.) line was established in an arm vein and once in place, a curtain was drawn 
which prevented the subject from viewing the I.V..  A minimum of 15 minutes elapsed between 
establishing the I.V. and beginning baseline rest.  Subjects were then exposed to the following 
conditions: 
Baseline Rest: Subjects rested alone for 10 minutes.  Blood  was sampled at minute 10 
for basal cortisol and NE concentrations. Plasma levels of NE were determined using the high-
pressure liquid chromatography with electrochemical detection (HPLC-ECD) technique.  The 
lower limit of quantification is 2.5 pg/ml, and the intra- and inter-day coefficients of variation are 
less than 10%.  Plasma cortisol was determined using radioimmunoassay techniques 
commercially available from MP Biomedical.  The sensitivity of the assay is .07 µg/dL and the 
specificity is high, showing .05–2.2% cross-reactivity with similar compounds, except 
prednisolone, where 94% cross-reactivity is obtained.  The intra- and inter-assay coefficients of 
variation from the cortisol assay were approximately 7.7% and 7.4%, respectively.  
 Pain Tests:  following baseline, subjects were exposed to the following pain tests, 
administered in random order with 5 minutes of rest between tests.  Neuroendocrine measures 
were not taken during the pain tests although the I.V. remained in place since a mental stress 
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battery followed the pain testing protocol (results to be reported elsewhere).  The arm used for 
pain induction was opposite to the one with the I.V. (chosen based on vein characteristics), and 
therefore was not selected based on dominance.   since the presence of an I.V. needle on the 
contralateral arm may have acted as a counter-irritant stimulus eliciting diffuse noxious 
inhibitory control mechanisms (R. R. Edwards, Ness, & Fillingim, 2004) and thereby altering 
pain sensitivity to the tests.  
Hand cold pressor 
 For the cold pressor task, participants submerged their hands to a marked line on their 
wrist in ice water maintained at 4°C.  A water circulator prevented water from warming near the 
subject’s hand. Subjects indicated when sensations in their hand first became painful (pain 
threshold) and when they were no longer willing or able to tolerate the pain (pain tolerance).  A 
maximum time limit of 5 minutes was imposed (Girdler Pain paper), though subjects were not 
informed of this limit. 
The Submaximal Effort Tourniquet Procedure 
 As described previously (Maixner, Gracely, Zuniga, Humphrey, & Bloodworth, 1990) a 
tourniquet cuff was positioned on the subject’s arm and the arm placed to the side.  Before 
inflating the tourniquet cuff to 200 mm Hg (Hokanson E20 Rapid Cuff Inflator), the subject’s 
arm was raised for 30 seconds to promote venous drainage, and then the cuff was inflated, the 
experimenter’s stopwatch started, and the arm returned to the side.  To promote ischemia, 
subjects engaged in 20 handgrip exercises at 30% of their maximum force.  Pain threshold and 
tolerance were determined as described above.  A maximum time limit of 20 minutes was 
enforced (Maixner and Gracely 1990 ref), though subjects were not informed of this limit. 
Pain intensity and unpleasantness 
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 Immediately before deflating the tourniquet cuff and before removal of the hand from the 
ice bath, subjects rated the intensity and unpleasantness of the test using a 0 - 100cm visual 
analogue scale.  Thus, ratings were provided before the tests was terminated. 
Data Reduction and Analysis 
 Due to the inability to obtain some blood samples, cortisol was available for 123 subjects 
and NE was available for 119 subjects.  First, demographic and historical variables were 
examined using a 2 (Abuse) X 2 (MRMD status) analysis of variance (ANOVA) for continuous 
variables and Pearson’s Chi-squared test or Fisher’s exact test for dichotomous variables as 
appropriate. Next, Ffor each dependent measure of pain sensitivity, as well as for endocrine 
measures, a 2 (Abuse) X 2 (MRMD status) analysis of covariance (ANCOVA) was employed, 
with age as the covariate while controlling for age (see Results).  Significant interactions (p<.05) 
were followed by t-tests post-hoc ANCOVA analyses adjusting for age.  Exploratory analyses 
among neuroendocrine data and pain data were examined using Pearson’s correlations (r).  In 
order to minimize the likelihood of spurious correlations resulting from small cell sizes, 
(n = 63), collapsed across abuse groups.  Emotional pain data were collected distally from 
neuroendocrine data and thus their relationships are not explored here.  Data were analyzed with 
PASW Statistics 18 (IBM, Chicago, Illinois, USA).   
Results 
Screening Outcomes 
From July 2007 through September 2011, 321 women presenting with MRMD were 
prospectively evaluated as described above.  Of these, 96 (30%) met MRMD criteria, 109 (34%) 
did not meet MRMD criteria (primarily due to not meeting symptom severity threshold criteria), 
110 (34%) withdrew or were lost to follow-up, and 7 (2%) were excluded due to a current Axis I 
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disorder (Need to fill this in). Of the 96 women with MRMD, four declined to participate in the 
research study, five did not meet eligibility criteria (one with polycystic ovarian syndrome, three 
with recent depression, and one with recent anorexia nervosa), and nine were lost to follow-up, 
yielding 76 women with MRMD who enrolled into the laboratory study.  Sixty three (83%) of 
these women with MRMD completed all aspects of testing and are included in the present report.    
During the same time frame, 127 women were prospectively evaluated as non-MRMD control 
women.  Of these, 84 (66%) met non-MRMD control status, 9 (7%) did not meet control criteria 
(primarily due to chronic affective symptoms), 26 (20%) withdrew or were lost to follow-up, and 
8 (6%) were excluded due to a current Axis I disorder (need to fill this in stills).  
 
Demographic and Historical VariablesAge, abuse histories and psychiatric histories 
Demographic characteristicsAge, type of abuse and psychiatric histories of all subjects, 
stratified by MRMD and abuse status are presented in Table 1.  There was a significant MRMD 
x Abuse interaction for age (F(3,125) = 4.23, p =.04) since MRMD women with abuse histories 
were younger when compared to MRMD women without abuse histories (t(61)=-2.45, p=.02).  
There was a significantly higher proportion of current smokers in women with MRMD women 
when compared to no-women without MRMD women (X2(1,125)=6.95, p=.008). The prevalence 
of sexual abuse only, physical abuse only, or any abuse history (sexual and/or physical abuse) 
was not different in MRMD women when compared to non-MRMD women due to targeted 
recruitment.  Moreover, the two abused groups did not differ in severity of their abuse.  Chi-
squared analyses indicated proportional differences as a function of MRMD status and abuse 
histories for prevalence of depression histories (X2(3,125)=15.27, p=.002) and PTSD histories 
(X2(3,125)=15.96, p=.001). Post-hoc tests indicated that histories of depression (X2 
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(1,62)=15.02, p<.001) and PTSD (Fisher’s exact test, p<.001) were significantly more prevalent 
in non-MRMD women with abuse histories when compared to non-MRMD women without 
abuse histories, while the prevalence of these psychiatric histories in MRMD women was not 
influenced by abuse status.  
Physical pain sensitivity in relation to MRMD status and Abuse history    
 After adjusting for age, we found that Ccold pressor pain tolerance was predicted by the 
interaction of MRMD and history of abuse (F(3,125) = 5.2077, p =.02; Figure 1).  MRMD 
women with abuse had lower tolerance levels than MRMD women without abuse (F(63)=7.15, 
p=.01)(t(61)=2.47, p=.02), while a history of abuse was not associated with a significant 
difference in pain tolerance in non-MRMD women.  There were no significant effects involving 
cold pressor pain threshold and unpleasantness (Table 2).  However, MRMD women had 
significantly higher cold pressor pain intensity ratings when compared to non-MRMD women 
regardless of abuse history (F(1,125)=6.18, p=.01)(F(1,125) = 6.19, p =.01).  (Table 2).  
 There was a marginal significancetrend for Tthe interaction of MRMD status and abuse 
history for predictinged tolerance to the ischemic pain task (F(3,123)=3.67, p=.058; Figure 
2)(F(3,123) = 4.25, p=.04; Figure 2).  MRMD women with abuse histories had a trend for lower 
ischemic pain tolerance than MRMD women without abuse (F(60)=3.54, p=.065; Figure 2)(t 
(60)=-1.81, p=.08; Figure 2), while abuse history was not associated with a significant difference 
in pain tolerance in non-MRMD women..  MRMD women had lower ischemic pain threshold 
values (F(1,123)-6.23, p=.01)( F(1,123) = 6.21, p=.01) and higher ischemic pain intensity ratings 
(F(1,124)=9.33, p=.003)( F(1,124) = 9.18, p=.003) when compared to non-MRMD women, 
regardless of abuse history (see Table 2).  There were no significant effects involving ischemic 
pain unpleasantness.   
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Emotional pain sensitivity in relation to MRMD status and Abuse history 
 The interaction of history of abuse and MRMD status significantly predicted follicular 
phase emotional pain sensitivity (F(3,125)=6.98, p=.009) (F(3,125) = 5.90, p =.02) (Figure 3).  
Non-MRMD women with abuse had greater emotional pain sensitivity compared with non-
MRMD women without abuse (F(61)=5.38, p=.02) (t(61)=2.23, p=.03), while a history of abuse 
did not predict emotional pain sensitivity in MRMD women in the follicular phase.  As expected, 
in the luteal phase MRMD women had greater emotional pain sensitivity than non-MRMD 
women (F(1,125) = 123.56, p <.001)(F(1,125) = 124.11, p <.001), but a history of abuse did not 
predict emotional pain sensitivity in either group in the luteal phase (Table 2).   
Plasma neuroendocrine measures in relation to MRMD and abuse  
 The interaction of abuse history and MRMD status predicted cortisol concentrations 
(F(3,122)=6.03, p=.02)(F(3,122) = 5.10, p=.03). MRMD women with abuse histories had lower 
cortisol concentrations than MRMD women without abuse histories (F(59)=7.11, p=.01; Figure 
4)(t(59)=-2.65, p=.01; Figure 4), while there were no differences in cortisol as a function of 
abuse history in non-MRMD women. There was also marginal significance a trend for the 
MRMD status and abuse historyies interaction (F(3,118)=3.40, p=.068), since in MRMD women 
abuse histories were associated with a trend for elevated norepinephrine concentrations 
(F(60)=3.82, p=.055). There were no significant group main or interactive effects involving 
plasma norepinephrine concentrations. 
 Since we observed main effects of MRMD status on pain sensitivity (described above), 
but not main effects of abuse status, correlational analyses were conducted separately in MRMD 
and non-MRMD groups, collapsing across abuse history groups.  As summarized in Table 3, for 
both MRMD and non-MRMD women, higher plasma cortisol concentrations predicted lower 
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cold pain unpleasantness ratings (r = -.30, p =.02 and r = -0.26, p =.04, respectively), and for the 
MRMD women, higher plasma cortisol also predicted higher cold pain tolerance levels (r = .32, 
p =.01).  In MRMD women, greater plasma NE concentrations were correlated with greater cold 
pain unpleasantness ratings (r = .26, p =.04).    
Discussion 
 The primary findings of this study are that in women with a MRMD, an abuse history is 
associated with enhanced sensitivity to physical pain stimuli (hyperalgesia), as evidenced by 
reduced pain tolerance to both cold pressor and ischemic pain, relative to other women with a 
MRMD but who had women with no abusesuch history.  In contrast, women withoutin non-a 
MRMD women, an abuse history was associated with enhanced emotional pain, measured here 
as sensitivity to interpersonal rejection, relative to other women without anon-MRMD who had 
women with no such abuse history.  These results suggest that MRMD status moderates the 
association of an abuse history with both physical and emotional pain sensitivity.  However, our 
results are also consistent with other reports (Fillingim et al., 1995; Straneva et al., 2002) that 
women with a MRMD women are hyperalgesic relative to non-MRMD women without a 
MRMD irrespective of abuse history since all women with a MRMD women had lower ischemic 
pain threshold levels and higher ischemic and cold pressor pain intensity ratings compared to all 
non-MRMD women.  Evidence suggests that  Since pain threshold and intensity reflect the 
sensory/discriminatory aspects of pain (e.g., pain threshold and intensity) and the 
affective/motivational dimensions of pain (e.g., pain tolerance and unpleasantness) involve 
different endogenous pain regulatory systems, while pain tolerance reflects the affective 
properties of pain (Gracely RH, Dubner R, McGrath PA.Science. 1979 Mar 23;203(4386):1261-
3; . Gracely RH, McGrath P, Dubner R. Pain. 1978 Jun;5(1):19-29).  Thus, the possibility exists 
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(Price, Harkins, & Baker, 1987), these results suggest that women with a MRMD may have a 
noxious stimuli, while an abuse history moderates the affective/motivational experience of pain 
in women with a MRMD.  This could then contribute to both the premenstrual somatic 
symptoms experienced by 80% of all women with MRMD (McHichi et al., 2002), and to the 
greater emotional and somatic premenstrual symptom severity experienced by MRMD women 
aMRMD who also have with an abuse history relative to other women with MRMD women with 
abuse history (Girdler et al., 2007). 
 It is unclear why we did not find that an abuse history influenced pain sensitivity in the 
women without a non-MRMD women, as two previous studies using thermal pain stimuli 
reported (Fillingim & Edwards, 2005; Granot et al., 2011).  One explanation might be that 
thermal heat is associated with a sharp, pricking heat sensation while both the cold pressor and 
ischemic pain tests induce a deep, tonic, aching sensation similar to that seen in clinical pain 
syndromes (Fillingim et al., 1996).  Moreover, sensitivity to tourniquet-induced ischemic pain 
involves endogenous opioid mechanisms (Frid et al., 1979, 1981), whereas sensitivity to cold 
pressor pain may be mediated by systemic vascular resistance and noradrenergic mechanisms 
(Girdler et al., 2005).  Thus, different endogenous pain regulatory mechanisms may be more or 
less modulated by histories of abuse.   
Our study is among the first to assess endogenous neuroendocrine pain regulatory 
mechanisms in MRMD.  For both the MRMD and the non-MRMD women, we found the 
expected relationship between elevated plasma cortisol and reduced sensitivity to cold pressor 
pain.  The relationship between elevated cortisol and decreased pain sensitivity has been 
documented in other studies (al’Absi et al., 2002; Girdler et al., 2005; Mechlin et al.,2005), and 
is thought to reflect an integrated, adaptive mechanism as part of the defense reaction, involving 
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nociceptive modulation by the HPA-axis.  Corticotrophin releasing hormone acts on a large 
number of brain structures involved in pain processing, including the locus coeruleus (LC), and 
HPA-axis factors can act both centrally and peripherally to produce analgesia (see Lariviere and 
Melzack, 2000 for review).  Since MRMD women with an abuse history showed significantly 
lower cortisol concentrations than MRMD women with no abuse history, hypocortisolima in 
MRMD women with prior abuse may contribute to their hyperalgesia.  Blunted HPA-axis 
function has been fairly consistently documented in MRMD samples compared with non-
MRMD controls (Girdler et al., 2003; Girdler, Straneva, Light, Pedersen, & Morrow, 2001; 
Redei & Freeman, 1993; Straneva et al., 2002), though not assessed by abuse status in these prior 
studies.  Hypocortisolimia has been observed in a number of disorders associated with pain, 
including fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome (Fries, Hesse, 
Hellhammer, & Hellhammer, 2005), conditions that are also associated with greater rates of 
abuse (Pratchett et al., 2010; Leserman & Drossman, 2007).  Regardless of mechanism(s), to the 
extent that sensitivity to experimental pain predicts clinical pain, our results for abuse-related 
hyperalgesia in MRMD women add to a body of work suggesting that histories of abuse predict a 
clinically distinct subgroup of MRMD women (Girdler et al., 2007; Girdler & Klatzkin, 2006). 
In contrast to the correlations involving higher cortisol concentrations and reduced 
sensitivity to pain, in MRMD women higher plasma NE concentrations were associated with 
increased cold pressor unpleasantness, a specific dimension of the pain experience (McGuire, 
DB, 1992, J Pain Symptom Manage.) ratings in MRMD women.  This seemingly contradicts 
both animal and human studies showing that higher concentrations of circulating NE are 
associated with increased pain tolerance (Girdler et al., 2005; Mechlin, Maixner, Light, Fisher, & 
Girdler, 2005; Sagen, Kemmler, & Wang, 1991).  However, in contrast to healthy, pain-free 
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control groups, studies in groups at risk for clinical pain have shown that higher, and not lower, 
plasma NE is associated with greater experimental pain sensitivity (Mechlin et al 2005; 2011).  
This is consistent with the findings in chronic pain patients who show a (reverse) 
hypersensitivity to NE, such that administration of NE increases pain, whereas it has no effect in 
healthy controls (Ali et al., 2000; Torebjork, Wahren, Wallin, Hallin, & Koltzenburg,1995).  
Higher circulating NE may reflect activation of LC neurons in brain, the major site of CNS 
adrenergic neurons.  The LC plays a critical role in modulating sensory input via descending pain 
inhibitory noradrenergic pain pathways (Maixner et al., 1989) and, like the HPA-axis, is 
involved in an integrated response to modulate nociception.  Thus, the finding that higher NE is 
associated with greater cold pressor pain unpleasantnesssensitivity in MRMD women may 
provide further support for alterations in endogenous pain regulatory mechanisms in MRMD, 
and may contribute to our findings that all MRMD women, regardless of abuse histories, 
exhibited hyperalgesia relative to non-MRMD women.  An alternative explanation, however, for 
the association between elevated plasma NE concentrations and cold pain unpleasantness ratings 
may relate to NE-induced vasoconstrictive actions that could independently evoke unpleasant 
painful sensations.  
In contrast to MRMD women, non-MRMD women with abuse histories were more 
sensitive to emotional pain relative to their non-abused counterparts, at least in the follicular 
phase, but were slightly (though not significantly) less sensitive to physical pain.  Others have 
also found a paradoxical relationship between rejection sensitivity and physical pain sensitivity 
in subjects where rejection was experimentally induced (MacDonald, Kingsbury, & Shaw, 
2005).  It has been proposed that rejection and physical pain both prime the fight or flight system 
but that flight is usually the best option up until the threat system is intensely activated at which 
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point the “fight” mechanisms engage, thereby decreasing physical pain sensitivity (MacDonald 
& Leary, 2005).  Consistent with this idea, and our findings, women who are very sensitive to 
rejection show decreased pain sensitivity in an experimental paradigm when exposed to a strong 
experimental rejection scenario (MacDonald, Kingsbury, & Shaw, 2005).  Thus, non-MRMD 
with abuse history may have also shown a non-significant decrease in sensitivity to experimental 
pain in our paradigm due to their greater rejection sensitivity. 
While we must acknowledge limitations of our study, including the relatively small 
MRMD x Abuse cell sizes, and the potential limited generalization of findings to non-MRMD 
women with abuse histories based on our selection strategies and requirement for the absence of 
current psychopathology, and lack of control for time of awakening which could affect cortisol 
concentrations (REF).  the study also has notable strengths.  Additionally, this is a cross sectional 
study that cannot demonstrate causality between MRMD status, a history of abuse and pain 
sensitivity.  Moreover, although we controlled for group differences in age in the analyses, abuse 
history groups also differed in rates of prior depression and PTSD which, while expected, could 
potentially confound the neuroendocrine and pain results.  MRMD groups also differed in 
smoking status, with more women with MRMD being smokers relative to women without 
MRMD.  This is consistent with the robust findings that patients with mood disorders are more 
likely to smoke (REF), but is unlikely to contribute to our findings for greater pain sensitivity in 
women with MRMD since, if anything, smokers are less sensitive to experimental pain tests than 
non-smokers (Girdler 2005, Pain). These limitations are balanced, in part, by the notable 
strengths of the study which include tThe use of daily prospective symptom ratings and a 
validated interview to determine MRMD and Abuse status, the use of two different physical pain 
tests that vary in underlying endogenous pain regulatory mechanisms, the prospective measure of 
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emotional pain sensitivity, and the inclusion of biomarkers of risk that are endogenous pain 
regulators., are among the strengths of the design.  
In conclusion, the results of our study suggestindicate that the presence of a MRMD 
moderates the relationship between an abuse history and sensitivity to both physical and 
emotional pain stimuli, and provides further evidence that a history of abuse may identify a 
clinically distinct subgroup of MRMD women with a MRMD.   
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Table 1: Age mean (SD), abuse histories and psychiatric histories n (%) of all participants and 
stratified by MRMD status and abuse status.  
 
Characteristics 
All women, 
n=126 
MRMD Non-MRMD 
Any abuse, 
n=34 
No abuse, 
n=29 
Any abuse, 
n=31 
No abuse, 
n=32 
Age (years) A 
34.2 (8.0) 31.9 (7.1) 36.5 (7.8) 34.9 (8.5) 33.7 (8.1) 
Non-Hispanic 
white  
82 (65) 24 (71) 19 (66) 21 (68) 18 (56) 
Education 
2.6 (.8) 2.3 (.8) 2.8 (1.0) 2.7 (.7) 2.7 (.8) 
Current smokers 
B 10 (8) 6 (18) 3 (10) 1 (3) 0 
Sexual abuse 
only 
22 (34) 13 (38) - 9 (29) - 
Physical abuse 
only  
18 (28) 10 (29) - 8 (26) - 
Sexual or 
physical abuse 
25 (39) 11 (32) - 14 (45) - 
 
  - 2.14 (1.36) - 
Depression 
history BC 
46 (37) 14 (41) 12 (41) 17 (55) 3 (9) 
Anxiety history 
21 (17) 6 (18) 7 (24) 7 (23) 1 (3) 
PTSD history BC 
16 (13) 3 (9) 3 (10) 10 (32) 0 (0) 
MRMD = menstrually related mood disorder; PTSD = post-traumatic stress disorder. 
Education: 1 = less than a high school education; 2 = high school degree; 3 = college degree, and 
4 = post-graduate degree. 
 
 
A MRMD women: abuse < no abuse, p <=.052p<.05 
B MRMD women > non-MRMD women, p < .01=.008 
B C Non-MRMD women: any abuse > no abuse, (p <.05) 
 
Formatted: Superscript
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Table 2. Physical pain sensitivity, emotional pain sensitivity and neuroendocrine measures 
stratified by MRMD status and any abuse status; mean (SD). 
 
 MRMD Non -–MRMD 
Any abuse, 
n=34 
No abuse, 
n=29 
Any abuse, 
n=31 
No abuse, 
n=32 
Cold pain  task 
Threshold (seconds) 22.3 (39.4) 25.0 (53.9) 26.2 (39.3) 25.1 (47.9) 
Tolerance (seconds) A 48.8 (59.3) 110.6 (123.4) 106.6 (120.9) 83.6 (103.4) 
Intensity (score) B 57.1 (22.8) 53.3 (18.1) 48.3 (20.4) 44.6 (17.2) 
Unpleasantness (score) 57.8 (20.3) 53.97 (23.3) 53.4 (23.2) 48.4 (23.6) 
Ischemic pain task 
Threshold (seconds) C 180.8 (187.7) 275.9 (279.6) 399.1 (387.1) 336.7 (357.7) 
Tolerance (seconds) AD 427.1 (318.7) 581.5 (354.4) 641.9 (431.7) 513.3 (413.6) 
Intensity (score) B 41.9 (21.9) 40.3 (17.5) 30.9 (18.8) 30.6 (17.5) 
Unpleasantness (score) 39.5 (21.2) 42.2 (18.5) 42.9 (17.0) 37.3 (17.4) 
Emotional pain sensitivity 
Luteal phase (score)  B 2.8 (.97) 2.9 (1.4) 1.3 (.4) 1.1 (.3) 
Follicular phase (score)  DE 1.3 (.4) 1.5 (.8) 1.4 (.8) 1.1 (.2) 
Neuroendocrine measures 
Cortisol ,( µg/dL) A 6.8 (2.7) 9.4 (4.8) 8.0 (2.2) 7.9 (3.1) 
Norepinephrine, (pg/mL) F 337.4 (202.2) 297.3 (92.4) 306.4 (77.8) 317.2 (107.2) 
MRMD = menstrually related mood disorder. 
A MRMD women only: any-abuse < no abuse, p<.05 
B MRMD > non-MRMD 
C MRMD < non-MRMD 
D MRMD women only: any-abuse < no abuse, p=.065 
D E Non-MRMD women only: any abuse > no abuse, p<.05; 
F MRMD women only: any-abuse > no abuse, p=.055 
Formatted Table
Formatted Table
Formatted Table
Formatted Table
Formatted Table
Formatted: Superscript
Formatted: Not Superscript/ Subscript
Formatted: Not Superscript/ Subscript
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Table 3. Pearson’s correlation coefficients (r) relating physical pain sensitivity and 
neuroendocrine measures in women stratified by MRMD status. 
 
 
MRMD women Non-MRMD women 
 Cortisol NE Cortisol NE 
Cold pressor pain task 
Tolerance .32  .01 -.07 .19 
Intensity -.24 .08 -.10 .04 
Unpleasantness -.30  .26  -.26  .03 
Ischemic pain task 
Tolerance .02 -.15 -.08 .05 
Intensity -.15 .18 -.03 -.03 
Unpleasantness -.09 .09 .01 .06 
In bold p≤.05 
MRMD = menstrually related mood disorder; NE = norepinephrine. 
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Figure legends. 
 
Figure 1: Cold pressor pain tolerance (in seconds) stratified by MRMD status and any abuse  
  status; mean (±SEM). 
Figure 2: Ischemic pain tolerance (in seconds) stratified by MRMD status and any abuse  
  status; mean (±SEM). 
Figure 3: Ratings of emotional sensitivity in the follicular phase of menstrual cycle  
  stratified by MRMD status and any abuse status; mean (±SEM). 
Figure 4: Cortisol concentrations (µg/dL) stratified by MRMD status and any abuse status;  
  mean (±SEM). 
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Figure 1. 
 
 
*MRMD women only: with abuse < without abuse, p=.012. 
 
 
Figure 2.  
 
 
* MRMD women only: with abuse < without abuse, p=.06508. 
Figure 3. 
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*non-MRMD women only: without abuse < with abuse, p=.0402. 
 
 
Figure 4. 
 
 
*MRMD women only: with abuse < without abuse, p=.01. 
 
